Smith & Nephew could use surgical activism 11 Oct 2017 U.S. hedge fund Elliott is building a stake in the artificial knee and hip maker. Talk that the company could be taken over has surfaced more often than actual bids. Agitating for bigger profit margins and a breakup may be more rewarding than hopes for a bigger deal.
P&G scores hollow victory over Nelson Peltz 10 Oct 2017 The $234 bln toiletries firm says the activist has lost his fight for a board seat. Peltz says the vote is too close to call. Either way, the narrow margin should be a wake-up call for P&G’s insular leaders, even if change comes hard for them. Expect Peltz to stick around.
Cox: P&G counting on an investor electoral college 6 Oct 2017 There's no strong reason for the insular consumer-goods titan to deny Nelson Peltz a board seat. Hedge funds will back him, but as in U.S. elections only half the retail shares may vote. That leaves Vanguard, BlackRock and State Street to play Wisconsin, Ohio and Pennsylvania.
Retailer puts huge discount on activist overreach 25 Sep 2017 Two hedge funds want to oust Tuesday Morning’s Steven Becker, a fellow pushy investor who ended up as CEO. The home-furnishing chain’s stock has fallen 62 pct on his watch - a reminder that having smart financial ideas doesn’t mean activists make good corporate chieftains.
Options hurt Bill Ackman’s cause at ADP 20 Sep 2017 The pushy hedge-fund boss owns most of his 8.3 pct stake in the $50 bln payroll processor with derivatives. It's a common ploy, but Ackman's plan is lackluster and investors can pick from plenty of activist campaigns. His choice of securities only makes it harder to gain support.
D.E. Shaw’s rare activist shot falls short at EQT 14 Sep 2017 The hedge fund is calling for a breakup of the natural-gas company, echoing Jana Partners. Yet it’s content to let the company first buy Rice Energy for $6.7 bln despite the deal’s flaws. It’s an unconvincing foray into activism for a fund better known for computerized trading.
Time isn’t always on Warren Buffett’s side 12 Sep 2017 Berkshire Hathaway’s bid to buy a fifth more of Home Capital was rejected by the Canadian lender’s shareholders. The setback comes weeks after Texas utility Oncor was snatched out from under Buffett's conglomerate. His opportunism is sometimes exposed on closer inspection.
Elliott takes activist-buyout firm fight to Japan 11 Sep 2017 The two Wall Street tribes are increasingly at odds. Now Elliott has bought into a $3 bln Hitachi unit that KKR covets, presumably seeking a better price. For private equity groups, mining Japan’s promising seam of corporate carve-outs may be about to get a little bit harder.
Peltz pulls his punches on P&G’s weak governance 7 Sep 2017 The Trian boss wants the $235 bln toiletries giant to restructure and pursue M&A to rev up growth. He blames directors for tolerating mediocrity yet declines to target any of them. It’s a missed opportunity. The company’s CEO-heavy board is bucking the tide of corporate America.
Elliott shows tail wags dog in German M&A 4 Sep 2017 The U.S. investor has nudged Bain and Cinven into paying minority shareholders in drugmaker Stada 12 pct more than others got last month. Germany’s odd rules and passive investing make it all too easy for holdouts who own small stakes to throw their weight around.
Europe’s consumer giants are overindulging on ads 1 Sep 2017 Companies like Nestlé and Danone spend twice as much on marketing than U.S. peers relative to sales. They defend such profligacy by pointing to superior revenue growth. True, sales are better, but not by much. With activists circling, plump ad budgets are ripe for cuts.
Elliott’s Stada shakedown is cheeky but rational 31 Aug 2017 The hedge fund wants the private equity firms buying drugmaker Stada to pay 74.40 euros for its minority stake. That’s nearly 50 pct above the firm’s value before Bain and Cinven began bidding. Yet Elliott has a point: the buyers could pay up and still make a respectable return.
Activists lack salve for hospitals’ financial ills 21 Aug 2017 Hefty debt, rising costs and painful changes to health insurance make the likes of Tenet and Community Health easy patients for pushy shareholders like Glenview. But the usual remedies will achieve little and there are few obvious buyers. Palliative care may end up an option.
Sempra $9.5 bln Oncor fine print bears close read 21 Aug 2017 The $29 bln energy company has bested Warren Buffett’s bid for the bankrupt utility and given pushy hedge fund Elliott a sweeter deal. But the transaction looks rushed and leaves Sempra with undisclosed partners and limited control. Such terms may give shareholders a nasty shock.
P&G’s best defense shouldn’t be a takeover offense 18 Aug 2017 As the consumer giant faces a proxy fight with activist Nelson Peltz, one idea doing the rounds is to consider an acquisition. The trick is to find a target as alluring as Gillette once was. The more obvious candidates - Colgate, Clorox and Kimberly-Clark - don't really stack up.
Ackman needs sharper ideas guys on his ADP payroll 17 Aug 2017 Activists succeed by pursuing clear, deliverable goals, such as ditching non-core units or removing failing executives. Urging the employer-services firm to become an agile software company is nothing of the sort. Investors are giving the Pershing Square boss a deserved raspberry.
Elliott is grasping at straws in Oncor battle 17 Aug 2017 The hedge fund says it has enough debt in the bankrupt utility to block Warren Buffett’s $18 bln offer. Yet the move makes little sense in the absence of a firm alternative. The judge is likely to see through Elliott’s posturing, as is the Omaha sage, who refused to up his bid.
Elliott finds part-victory in Akzo defeat 16 Aug 2017 The U.S. activist failed to arm-twist the Dulux paint maker into a merger with PPG. The Dutch group has, though, committed to a full breakup and put two solid new members on the board. It’s a decent result for Akzo’s investors – although less than Elliott’s might have wanted.
Danone can stomach new activist investor 15 Aug 2017 Hedge fund Corvex’s reported stake in the yoghurt maker may be small, but it puts pressure on management to meet its new margin target. Danone was once shielded from a Pepsi bid by the French state. If new investors bring good ideas and discipline, such defences won’t be needed.
Akzo and Elliott are trapped in a lose-lose battle 11 Aug 2017 The Dutch paint maker has won a legal victory over its biggest shareholder, which is trying to oust the chairman. The increasingly pointless fight is likely to drag on beyond September’s shareholder meeting unless new CEO Thierry Vanlancker can make both sides see sense.